0
0
0
s2sdefault

The tobacco giant behind the Marlboro man has sparked outrage in medical circles over a bid to invest in a company that develops inhaler technology, which could see it profit from the smoking-related lung diseases it helped create. Philip Morris International is in the middle of a takeover bid over for Vectura, a UK company that specialises in inhaler technology for lung illnesses.

In Australia, experts say it could threaten research and force doctors to change the way they treat some patients with lung disease. There are also concerns the deal could put Australia in breach of a global treaty.